| ULTIMORPHIX TECHNOLOGIES B.V. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110288045 | WET GRANULATION OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ - The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known degradation products. | 11-24-2011 |
| 20110009368 | SOLID FORMS OF TENOFOVIR DISOPROXIL - The Present Invention Provides Tenofovir Disoproxil Succinate, Tenofovir Disoproxil L-Tartrate, Tenofovir Disoproxil oxalate, Tenofovir disoproxil saccharate, Tenofovir disoproxil citrate, Tenofovir disoproxil salicylate and various solid forms thereof, methods for the preparation thereof and their use in pharmaceutical applications, in particular in anti-HIV medicaments. The forms of Tenofovir disoproxil can be used in combination with other anti-HIV medicaments such as Efavirenz and Emtricitabine. | 01-13-2011 |
| 20090270352 | Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal - The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114. | 10-29-2009 |
| 20090176983 | Tenofovir Disoproxil Hemi-Fumaric Acid Co-Crystal - The present invention provides a novel crystalline form of Tenofovir disoproxil fumarate (Tenofovir DF), designated Co-crystal TDFA 2:1, methods for the preparation thereof and its use in pharmaceutical applications, in particular in anti-HIV medicaments. The crystalline form TDFA 2:1 can be used in combination with other anti-HIV medicaments such as Efavirenz, Emtricitabine, Ritonavir and/or TMC114. | 07-09-2009 |
